Exponent (EXPO) Projected to Post Quarterly Earnings on Thursday

Exponent (NASDAQ:EXPO) is expected to be issuing its Q4 2025 results after the market closes on Thursday, February 5th. Analysts expect the company to announce earnings of $0.47 per share and revenue of $128.48 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 5, 2026 at 4:30 PM ET.

Exponent Price Performance

Shares of NASDAQ EXPO opened at $73.66 on Tuesday. The business has a 50-day moving average of $72.98 and a two-hundred day moving average of $70.95. The company has a market capitalization of $3.67 billion, a price-to-earnings ratio of 35.93 and a beta of 0.79. Exponent has a 1 year low of $63.81 and a 1 year high of $97.57.

Exponent announced that its Board of Directors has authorized a stock repurchase program on Thursday, October 30th that allows the company to buyback $100.00 million in outstanding shares. This buyback authorization allows the business services provider to reacquire up to 3% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on EXPO. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Exponent in a report on Thursday, January 22nd. William Blair upgraded shares of Exponent from a “market perform” rating to an “outperform” rating in a report on Monday, November 17th. JPMorgan Chase & Co. assumed coverage on shares of Exponent in a research note on Monday, January 26th. They set an “overweight” rating and a $100.00 price target on the stock. Finally, UBS Group reissued a “neutral” rating and issued a $81.00 price target (up from $76.00) on shares of Exponent in a research report on Monday, December 15th. Two research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $90.50.

Insiders Place Their Bets

In other Exponent news, CEO Catherine Corrigan sold 1,663 shares of the firm’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $72.52, for a total transaction of $120,600.76. Following the transaction, the chief executive officer directly owned 92,723 shares of the company’s stock, valued at approximately $6,724,271.96. This trade represents a 1.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In the last ninety days, insiders have sold 9,788 shares of company stock worth $693,648. 1.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Exponent

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. FORA Capital LLC acquired a new position in Exponent during the second quarter worth $228,000. United Services Automobile Association acquired a new position in shares of Exponent during the 1st quarter worth $270,000. Brevan Howard Capital Management LP acquired a new position in shares of Exponent during the 3rd quarter worth $324,000. Corient Private Wealth LLC increased its holdings in shares of Exponent by 57.0% in the 2nd quarter. Corient Private Wealth LLC now owns 4,793 shares of the business services provider’s stock valued at $358,000 after purchasing an additional 1,741 shares in the last quarter. Finally, Quantinno Capital Management LP lifted its stake in shares of Exponent by 44.1% in the second quarter. Quantinno Capital Management LP now owns 4,872 shares of the business services provider’s stock valued at $364,000 after purchasing an additional 1,490 shares during the period. Hedge funds and other institutional investors own 92.37% of the company’s stock.

About Exponent

Exponent, Inc (NASDAQ: EXPO) is an engineering and scientific consulting firm that offers multidisciplinary analysis and advisory services to clients across a range of industries. The company’s expertise spans mechanical, materials and corrosion engineering, civil and structural engineering, electrical engineering, industrial hygiene, toxicology and health sciences, and failure analysis. Exponent provides support for product design, performance evaluation, litigation consulting, and regulatory compliance, helping manufacturers, insurers, law firms and government agencies address complex technical challenges.

Founded in 1967 in Menlo Park, California, Exponent has grown from a small failure-analysis laboratory into a global consulting practice.